I-Mab Biopharma and Bio-Cancer Treatment International Announce Intention for Collaboration on Arginine Depletion Therapy and Biomarker Study, with Plans for I-Mab to Establish a Translational Medicine Lab in Hong Kong

HONG KONG, Feb. 1, 2019 /PRNewswire/ — I-Mab Biopharma (I-Mab), a China-based clinical stage biopharmaceutical company exclusively focused on the development of innovative biologics in immuno-oncology and autoimmune diseases, today announces that it has entered into a memorandum of…

Source: https://www.prnewswire.com:443/news-releases/i-mab-biopharma-and-bio-cancer-treatment-international-announce-intention-for-collaboration-on-arginine-depletion-therapy-and-biomarker-study-with-plans-for-i-mab-to-establish-a-translational-medicine-lab-in-hong-kong-300788081.html